Ongoing Clinical Trials for Raynaud’s Phenomenon
There is currently 1 clinical trial ongoing for Raynaud’s phenomenon, investigating whether the medication Clopidogrel can help prevent the development of systemic sclerosis in patients who experience symptoms and have specific immune system characteristics. The trial is being conducted in France and is expected to run for several years.
Clinical trial locations
Study on Clopidogrel’s Effect in Preventing Systemic Sclerosis for Patients with Raynaud’s Phenomenon and Specific Immune Conditions
This trial is investigating whether Clopidogrel, a medication normally used to prevent blood clots, can help reduce the risk of developing systemic sclerosis in people who have Raynaud’s phenomenon along with specific immune system markers. Systemic sclerosis is a rare condition that causes hardening and tightening of the skin and connective tissues throughout the body.
Who can participate:
- Adults between 18 and 85 years old
- People who have Raynaud’s phenomenon, confirmed by a doctor. This is a condition where fingers and toes change color and may feel numb or painful when exposed to cold or stress
- Individuals with a positive test for antinuclear antibodies (proteins made by the immune system) at a level of 1/160 or higher, with specific types related to systemic sclerosis such as anti-Scl70, anti-centromere, or anti-RNApolIII
- Those who are affiliated with a health insurance system
- Participants must agree to take part in the study and sign an informed consent form
Who cannot participate:
- People who have medical conditions other than Raynaud’s phenomenon
- Those outside the specified age range
- Individuals who are not willing to follow the study procedures
- People belonging to vulnerable populations that the study is not including
What the trial involves: Participants will be randomly assigned to receive either Clopidogrel (marketed as Plavix 75 mg film-coated tablets) or a placebo, taken orally. The treatment will continue for up to 5 years, with regular check-ups and assessments to monitor for any signs of systemic sclerosis or related symptoms. The main goal is to determine whether Clopidogrel can effectively prevent the onset of systemic sclerosis in people who are at higher risk due to their immune profile and symptoms.
Investigational drug: Clopidogrel works by blocking receptors on platelets (blood cells involved in clotting), preventing them from clumping together. In this trial, researchers are studying whether this antiplatelet medication might have a protective effect against the development of systemic sclerosis in at-risk individuals.
Throughout the study, participants’ health and safety will be closely monitored by medical professionals, with regular clinical evaluations by independent investigators. The trial is expected to conclude by June 30, 2030.
Summary
Currently, there is one ongoing clinical trial for Raynaud’s phenomenon, taking place in France. This trial focuses specifically on prevention rather than treatment of existing symptoms, investigating whether Clopidogrel can reduce the risk of progression to systemic sclerosis in patients with Raynaud’s phenomenon who have specific immune markers. The study represents an innovative approach to potentially preventing a serious complication in at-risk individuals. The trial will run for several years, reflecting the long-term nature of evaluating preventive treatments for chronic conditions.
